Impact of biomarker development on drug safety assessment.
Drug safety has always been a key aspect of drug development. Recently, the Vioxx case and several cases of serious adverse events being linked to high-profile products have increased the importance of drug safety, especially in the eyes of drug development companies and global regulatory agencies. Safety biomarkers are increasingly being seen as helping to provide the clarity, predictability, and certainty needed to gain confidence in decision making: early-stage projects can be stopped quicker, late-stage projects become less risky. Public and private organizations are investing heavily in terms of time, money and manpower on safety biomarker development. An illustrative and "door opening" safety biomarker success story is the recent recognition of kidney safety biomarkers for pre-clinical and limited translational contexts by FDA and EMEA. This milestone achieved for kidney biomarkers and the "know how" acquired is being transferred to other organ toxicities, namely liver, heart, vascular system. New technologies and molecular-based approaches, i.e., molecular pathology as a complement to the classical toolbox, allow promising discoveries in the safety biomarker field. This review will focus on the utility and use of safety biomarkers all along drug development, highlighting the present gaps and opportunities identified in organ toxicity monitoring. A last part will be dedicated to safety biomarker development in general, from identification to diagnostic tests, using the kidney safety biomarkers success as an illustrative example.
Marrer
Estelle
E
Translational Sciences, Novartis Institutes for Biomedical Research, CH-4002 Basel, Switzerland.
Dieterle
Frank
F
D000818:Animals; D015415:Biomarkers; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000378:metabolism; D064420:Drug-Related Side Effects and Adverse Reactions; D006331:Heart Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism; D006801:Humans; D007674:Kidney Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism; D012449:Safety; D014652:Vascular Diseases / Q000139:chemically induced / Q000175:diagnosis / Q000378:metabolism
D015415:Biomarkers